共 48 条
- [1] Baden LR(2021)Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine N Engl J Med 384 403-416
- [2] El Sahly HM(2020)Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine N Engl J Med 383 2603-2615
- [3] Essink B(2020)Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’ Ann Rheum Dis 79 1156-1162
- [4] Kotloff K(2021)Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey RMD Open 7 e001814-709
- [5] Frey S(2022)Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry Ann Rheum Dis 81 695-ee50
- [6] Novak R(2022)Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study Lancet Rheumatol 4 e338-1638
- [7] Polack FP(2021)Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis Ann Rheum Dis 80 1635-e11
- [8] Thomas SJ(2022)Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry Lancet Rheumatol 4 e8-undefined
- [9] Kitchin N(undefined)undefined undefined undefined undefined-undefined
- [10] Absalon J(undefined)undefined undefined undefined undefined-undefined